BAVARIAN NORDIC A/S

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 79176
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 6899
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 1283
 
  
 
C07K PEPTIDES 12124
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1287
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 8117
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247
 
  
 
C10N INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M 13
 
  
 
C12M APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY 148
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1205

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0266,270 Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint InhibitorMay 08, 15Sep 21, 17[A61K, C12N, C07K]
2017/0137,820 AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR (TLR) 13Jan 27, 17May 18, 17[A61K, C12N]
2017/0128,561 USE OF OIL AND WATER EMULSIONS FOR INCREASING B CELL RESPONSES WITH MODIFIED VACCINIA ANKARA VIRUSMar 12, 15May 11, 17[A61K]
2017/0106,065 Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3May 08, 15Apr 20, 17[A61K, C12N, C07K]
2017/0081,642 RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT COct 07, 16Mar 23, 17[C12N, C07K]
2016/0376,596 COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORSNov 25, 14Dec 29, 16[A61K, C12N]
2016/0271,239 Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint InhibitorOct 31, 14Sep 22, 16[A61K, C12N]
2015/0283,220 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCEROct 16, 13Oct 08, 15[A61K, C12N]
2012/0328,650 MODIFIED VACCINIA ANKARA VIRUS VARIANTAug 17, 12Dec 27, 12[A61K, A61P]
2012/0183,574 MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATESMar 16, 12Jul 19, 12[A61K, A61P]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9828414 Pr13.5 promoter for robust T-cell and antibody responsesOct 28, 13Nov 28, 17[A61K, C12N, C07K]
9717787 Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccineOct 14, 16Aug 01, 17[A61K, C12Q, C12N, C07K]
9707291 Single high dose of MVA induces a protective immune response in neonates and infantsMar 14, 14Jul 18, 17[A61K]
9556439 Agonists and antagonists of toll-like receptor (TLR) 13Feb 08, 13Jan 31, 17[A61K, C12N]
9540660 Vector comprising multiple homologous nucleotide sequencesMar 09, 15Jan 10, 17[C12N]
9480738 Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccineMar 15, 13Nov 01, 16[A61K, C12Q, C12N]
9463238 Recombinant poxvirus vector comprising tetanus toxin fragment CNov 30, 12Oct 11, 16[A61K]
9265823 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agentsJul 10, 14Feb 23, 16[A61K, C12N]
9173933 Recombinant modified vaccinia virus Ankara influenza vaccineOct 07, 11Nov 03, 15[A61K, C12N]
9163237 Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elementsDec 04, 13Oct 20, 15[A61K, C12N, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2014/0342,403 PROMOTERS FOR RECOMBINANT VIRAL EXPRESSIONAbandonedJun 03, 14Nov 20, 14[C12N]
2012/0135,032 GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIVAbandonedOct 06, 10May 31, 12[A61K, A61P]
8147839 Fusion proteins of HIV regulatory/accessory proteinsExpiredNov 03, 09Apr 03, 12[A61K, C12N]
8142796 Monoparamunity inducers based on attenuated rabbit myxomavirusesExpiredAug 06, 10Mar 27, 12[A61K, C12N]
8143054 Fusion protein of HIV regulatory/accessory proteinsExpiredJun 24, 09Mar 27, 12[A61K, C12N]
8137931 Fusion proteins of HIV regulatory/accessory proteinsExpiredNov 03, 09Mar 20, 12[A61K, C12N]
8039004 Methods of preparing myxomavirus compositionsExpiredSep 28, 10Oct 18, 11[A61K]
8034356 Monoparamunity inducers based on attenuated rabbit myxoma virusesExpiredSep 28, 10Oct 11, 11[A61K, C12N]
2011/0142,877 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agentsAbandonedAug 23, 07Jun 16, 11[A61K, A61P]
7939085 Monoparamunity inducers based on attenuated rabbit myxomavirusesExpiredFeb 28, 08May 10, 11[A61K, A01N, C12Q, C12N]
2011/0052,627 RECOMBINANT MODIFIED VACCINIA VIRUS MEASLES VACCINEAbandonedJun 08, 09Mar 03, 11[A61K, C12N, A61P]
2011/0014,242 PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARAAbandonedSep 10, 10Jan 20, 11[A61K, C07H, C12P, C12N, A61P]
2011/0008,792 PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARAAbandonedSep 10, 10Jan 13, 11[C12Q]
7816508 Promoters for expression in modified vaccinia virus AnkaraExpiredOct 27, 04Oct 19, 10[C07H, C12N]
7691391 Monoparamunity inducers based on attenuated rabbit myxomavirusesExpiredFeb 28, 08Apr 06, 10[A61K]
2010/0011,451 PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINSAbandonedSep 06, 07Jan 14, 10[A61K, C12Q, A61P]
7569228 Fusion proteins of non-attenuated HIV regulatory/accessory proteinsExpiredJul 18, 06Aug 04, 09[A61K]
2009/0148,405 INDUCTION OF DENDRITIC CELL DEVELOPMENT WITH MACROPHAGE-COLONY STIMULATING FACTOR (M-CSF) RECEPTOR LIGANDSAbandonedDec 22, 08Jun 11, 09[A61K, C12Q, C12P, C12N]
7494799 Paramunity inducers based on attenuated rabbit myxoma virusExpiredJan 21, 05Feb 24, 09[A61K, C12Q, C12P, C12N]
7473536 Isolated avian cell that expresses Vaccinia virus host range genesExpiredJul 29, 03Jan 06, 09[A61K, C12P]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.